Kornimate/medical-research-clean huggingface dataset:
stress response to virtual risky movement exposure and kinesiophobia after anterior cruciate ligament (acl) surgery

Conditions: Kinesiophobia; Anterior Cruciate Ligament Injuries

Summary: in this study, patients who have completed their rehabilitation after anterior cruciate ligament (acl) reconstruction surgery will be examined with physiological stress response test while being exposed to risky athletic movements via virtual reality headsets. in the next, step patients' functional performance tests will be examined and their relation with stress responses will be examined.


Eligibility criteria:
inclusion criteria for study group: * 18 years or older * male gender * having history of isolated unilateral acl reconstruction surgery * physician clearance for unrestricted physical activity after having at least 6-months of rehabilitation following surgery * willing to return to sports that require cutting and landing motions * not having any sports injuries past three months * not having any previous orthopaedic surgery other than acl reconstruction surgery inclusion criteria for control group: * 18 years or older * male gender * playing sports that require cutting and landing motions * physician clearance for unrestricted physical activity * not having any sports injuries past three months * not having any previous orthopaedic surgery exclusion criteria for study group: * having a reinjury during rehabilitation * having multiple ligament injuries before the surgery * diagnosed with knee osteoarthritis * diagnosed with knee cartilage injury * diagnosed with meniscus tear exclusion criteria for control group: * diagnosed with acl injury * diagnosed with knee osteoarthritis * diagnosed with knee cartilage injury * diagnosed with meniscus tear

Keywords: kinesiophobia anterior cruciate ligament injuries virtual reality stress athlete sports medicine
changes in insulin resistance in healthy volunteers on stribild® medication

Conditions: Insulin Resistance

Summary: changes in insulin resistance in healthy volunteers with normal body weight (bmi 18-25) after 14 days of stribild®-, truvada®/kaletra® or truvada®/prezista®/norvir® intake, measured by hyperinsulinemic euglycemic clamp.

the measurement of insulin resistance will be performed in 30 hiv-negative healthy non-obese (bmi 18-25) male volunteers before and after 14 days (+/- 2 days) of treatment with stribild® (treatment 1, n=10), as compared to tvd, lpv/r (treatment 2, n=10) and tvd, drv/r (treatment 3, n=10). the volunteers will be randomly assigned to one of three groups. the measurement of insulin resistance, lipid and glucose metabolism will be performed; before and immediately after the treatment. furthermore, the therapy compliance will be verified using the method of drug counting and therapeutic drug monitoring (tdm).

Eligibility criteria:
inclusion criteria: * healthy male volunteers, age 18-40 years * informed consent and willingness in study participation * birth control during study period exclusion criteria: * participation in other clinical trials * contraindication or known allergy to study medication * known metabolic disease incl. diabetes mellitus, hypertriglyceridemia or others * known alcohol or nicotine abuse * hiv infection * history of pharmaceutical study in the last 4 weeks * bmi \ 25 * long-term or regular medication * known liver-, renal-, cardiovascular, lung, gastrointestinal, endocrine, neurologic, psychiatric or metabolic disorder * dependence to study center or coordinator * inmates or psychiatric treatment

Keywords: art, hiv, insulin resistance
lowering blood pressure in primary care in vienna

Conditions: Hypertension

Summary: the aim of this prospective, randomised, open-label, multicentre clinical trial is to enhance blood pressure control in primary care by introducing a standardised and simplified titration regime with single pill combinations (spc), comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.

rationale hypertension is the single largest contributor to mortality worldwide, accounting for 13% of deaths globally. approximately 30% of the adult population suffer from hypertension and of those diagnosed and treated, only 30-50% have adequately controlled blood pressure. at present, the importance of hypertension as fundamental risk factors is inadequately addressed among many patients and physicians. design the aim of this prospective, randomised, open-label, multicentre clinical trial is to enhance blood pressure control in primary care by introducing a standardised and simplified titration regime with single pill combinations (spc), comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide. the trial will randomise 42 family doctors or resident specialists for internal medicine (enrolling 840 patients with treated or untreated hypertension) to either experimental care or standard care for hypertension, latter according to the 2013 european society of cardiology guidelines for the management of arterial hypertension. practitioners randomised to experimental care will up-titrate antihypertensive therapy with spcs in 4-week intervals if the target blood pressure of \< 140/90 mmhg is not reached at the respective follow-up (figure 1). study outcomes the primary efficacy endpoint will be the proportion of patients achieving the target office blood pressure after 6 months of follow-up. the main secondary endpoint will be the improvement of 24h ambulatory blood pressure (abpm) profile, measured at inclusion and after 6 months of follow-up. safety assessments include the evaluation of treatment emergent adverse events, particularly hospitalisation, worsening of renal function, peripheral oedema and hypotension.

Eligibility criteria:
inclusion criteria: * written informed consent * office blood pressure ≥ 140/90 mmhg * ace inhibitor intolerance (experimental arm) exclusion criteria: * malignant disease with life expectancy \< 6 months * women of childbearing potential (ich definition) or breastfeeding * contraindications or allergies against olmesartan, amlodipine or hydrochlorothiazide (experimental arm) * chronic kidney disease grade iv or v (egfr \< 30 ml/min) * recent myocardial infarction or stroke within the preceding 3 months * participation in another clinical trial
the aim of this study is to investigate the correlation between the severity of glaucoma and corneal biomechanics as well as anterior chamber parameters.

Conditions: Glaucoma

Summary: the ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma


Eligibility criteria:
inclusion criteria: * clinical diagnosis of primary glaucoma. * must be able to cooperate to complete the inspection. exclusion criteria: * secondary glaucoma. * corneal disease (e. g., keratitis, corneal scarring) that the investigator believes may affect the examination. * trauma * congenital eye malformations
icam clinical validation study

Conditions: Eye Disease

Summary: comparison study to assess photo image quality of a new color fundus camera compared to that of a commercially available color fundus camera.

optovue has developed a new color fundus camera for imaging the eye with up to 45 degree field of view and without the use of dilating drops. the purpose of the study is to compare the image quality of the new camera with that of a commercially available color fundus camera. consented subjects will undergo a general ophthalmic examination and series of fundus photography exams using the study device and comparison device. photo image quality will be assessed for determination of clinically usefulness.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * able and willing to complete the required examination exclusion criteria: * spherical equivalent outside -12 diopter to +15 diopter * without lens * inability to fixate

Keywords: without eye disease
detection of cytomegalovirus virus in neonates

Conditions: CMV

Summary: to evaluate the illumigene cmv assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs


Eligibility criteria:
inclusion criteria: * saliva swab specimens from neonates up to 21 days of age * saliva swab sample placed in a nonnutritive transport medium or in a plastic sterile tube without medium. * flocked-nylon swabs exclusion criteria: * samples other than saliva swab from patients up to 21 days of age. * swabs other than flocked-nylon. * swabs in a viral transport media not defined in the investigational use only package insert * multiple specimens from the same patient. * specimens received in the laboratory in unsatisfactory containers or condition.
incobotulinum toxin a (xeomin®) as a treatment for focal task-specific dystonia of the musician's hand

Conditions: Dystonia

Summary: the investigational drug being studied in this protocol is incobotulinumtoxin a (xeomin®). botulinum toxin (bont) prevents the release of the acetylcholine from peripheral nerves, inhibiting muscle contractions. bont is effective in relaxing overactive muscles. in musician's dystonia, the ability to reduce abnormally overactive muscles in the hand can be critical for the musical professional to continue his or her career. with the use of emg/electrical stimulation and/or ultrasound guidance, the injector can precisely localize the individual muscles that are affected in this condition with great accuracy. prior studies have shown that bont injections produce beneficial effects in forearm muscles, and less effect in shoulder or proximal arm muscles. possible risks in treating patients with bont include excessive weakness of the injected muscles. the drug may also affect non-targeted muscles. however these risks will be minimized during the screening period by carefully targeting the affected muscles and by administering low doses of bont. small booster doses may be given at follow up visit (2, 4, 14 and 16-weeks after the primary injection date) if the initial injection was insufficient to produce sufficient efficacy in relief of the focal dystonia and did not produce excess weakness of the targeted muscle.


Eligibility criteria:
inclusion criteria: * patients with focal task-specific dystonia of one or both hands, selectively triggered by performance on a musical instrument. * patients must have been evaluated by dr. frucht at the movement disorders division of mount sinai medical center as part of their clinical care. * patients whose performance on an instrument is directly linked to their occupation. * patients must be between the ages of 18 and 80. * impairment in musical performance must be visible and demonstrable. exclusion criteria: * patients whose dystonia is not severe enough to interfere with musical performance in the opinion of a skilled examiner. * patients with unstable medical conditions or psychiatric conditions. * patients with a medical condition that precludes them from receiving bont injections.

Keywords: musician's dystonia
effectiveness of atypical versus conventional antipsychotics in treating schizophrenia

Conditions: Schizophrenia

Summary: this study will compare the effectiveness of newer atypical antipsychotics versus older conventional antipsychotics in treating schizophrenia.

at seven participating hospitals, acutely exacerbated patients with schizophrenia were randomly assigned to treatment with antipsychotic from the atypical class vs antipsychotic from the conventional class. medication choice within class, dose, concomitant medications, and other prescribing decisions were left to the community prescriber. patients were followed for one year after discharge.

Eligibility criteria:
inclusion criteria: * hospitalized for schizophrenia exclusion criteria: * none
phase ii trial of sunitinib in bac or never-smokers with any lung adenocarcinoma

Conditions: Lung Cancer; Adenocarcinoma

Summary: this is an open-label study of a new oral drug for advanced stage (iiib or iv) lung cancer. the cancer must be either bronchoalveolar carcinoma (bac) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.

to participate in this study, patients must have disease that can be measured on a ct scan. brain metastases are ok if stable. pregnant and/or nursing women may not participate. this drug has been approved by the fda for the treatment of advanced renal cell cancer and a certain type of stomach/intestinal cancer. its efficacy in lung cancer in currently unknown. common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood counts.

Eligibility criteria:
inclusion criteria: * bronchoalveolar carcinoma with disease measurable on cat scan * any lung adenocarcinoma in a never-smoker (less than 100 cigarettes lifetime) with disease measurable on cat scan * stage iiib or iv exclusion criteria: * uncontrolled hypertension * unstable brain metastases * pregnant/nursing women * uncontrolled thyroid disease

Keywords: bronchoalveolar carcinoma bac adenocarcinoma lung cancer oral stage iiib and iv lung cancer any bronchoalveolar carcinoma (bac) any adenocarcinoma in a never-smoker
effects of navigated repetitive transcranial magnetic stimulation according to post-stroke aphasia types

Conditions: To Healthy Volunteer; Virtual Lesions for Aphasia

Summary: repetitive transcranial magnetic stimulation induced virtual lesions for aphasia.

to evaluate the effect of navigated repetitive transcranial magnetic stimulation in subjects with aphasia after stroke.

Eligibility criteria:
inclusion criteria: * fluent in korean * older than 18 years old exclusion criteria: * younger than 18 years old * psychotic or psychiatric problems * pregnant * contraindications to mri/fmri * uncooperative * metalic implants, pacemaker or cochlear implants * cannot perform outcome measure-related task * known seizure history
the use of chlorhexidine and a probiotic lozenge in the nonsurgical therapy of periodontitis

Conditions: Periodontitis; Chlorhexidine; Probiotic

Summary: the aim of this study is determining the additional effect of a 2-week home usage of chlorhexidine in periodontitis patients undergoing scaling and root planing supplemented with a dual-strain probiotic lozenge.


Eligibility criteria:
inclusion criteria: * diagnosed with generalized (\>30% of teeth affected) periodontitisstage iii and iv periodontitis, grade b or c (c only with smoker modifier) = generalized chronic periodontitis including smokers * a minimum of three natural teeth in each quadrant, excluding third molars * willing and able to give informed consent * not more than 50% of the patients in each group will be smokers. * smokers should smoke between 10 to 40 cigarettes a day exclusion criteria: * patients with localized periodontitis or periodontitis stage i or ii or grade a or grade c or grade c with diabetes modifier * patients with orthodontic appliances (removable or fixed) * pregnant or lactating woman * patients with a history of systemic diseases that may correlate with periodontal health, such as diabetesrheumatic fever, liver or kidney disease, and neurological deficiencies * patients taking medication which may affect the periodontium (bisphosphonates, phenytoin, cyclosporin, nifidepine, chronic use of non-steroidal anti-inflammatory drugs) * patient who had taken systemic antibiotics up to 3 months prior to treatment or medical conditions requiring prophylactic antibiotic coverage * participation in any other clinical study * tobacco chewing or sniffing
step by step after cancer

Conditions: Breast Cancer

Summary: after treatment, women want to regain a 'normal' lifestyle while some factors interfere as chronic fatigue. in the absence of anemia, fatigue is often a consequence of physical deconditioning . the following protocol will focus at this problem.it will consist of a brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of hr pic during 20 minutes.

pinto and colleagues, for a walking level from 55 to 65% hrmax, estimated a reduction of fatigue in post treatment. supervised exercise show greater adherence to short-term practice at home. however, there are a growing number of studies suggesting a practice at home, the most activity being walking. the authors do not justify the choice of the type of supervision. but physical activity with a professional and / or group in a specific place definitely has different effects in relation to practice at home. segal and his colleagues in 2001 for the first time wished to compare the two types of supervision. the results are in favor of supervised exercise. the training was identical. however, to answer the five weekly sessions requested, the patient group had to complete two supervised practice sessions at home. so, the investigators really can not quantify the difference in impact between home practice and supervised practice. in a meta-analysis, velthuis and colleagues conclude a significant difference in fatigue during treatment for a supervised aerobic exercise against a home that does not show significant difference. if the training is the same in both situations, the investigators should not find any difference in physiologic responses. however, the psychological impact can vary from one situation to another. the following protocol will focus at this problem. it will consist of a brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of hr pic during 20 minutes. biweekly session from 60% of the heart rate pic during 20 minutes will be proposed. each patient of supervised walking group will meet the student each session. each patient of home-based walking group will be called by phone every week by the student to inform the patient of the progress of the training, collect the work and answer any questions.

Eligibility criteria:
inclusion criteria: * sex: female * age less than or equal to 75 years * breast cancer stage i to iii * chemotherapy and / or radiotherapy adjuvant completed * hormone treatments ongoing exclusion criteria: * age over 75 years * breast cancer stage iv and o * anemia, cardiac arrhythmia, asthma, hypertension or uncontrolled diabetes, coronary artery disease or severe respiratory disease, psycho-cognitive may disturb walking program

Keywords: hormonal therapy walking fatigue
effects of ba duan jin training for older people

Conditions: Exercise; Old Age

Summary: baduanjin is one of the widely circulated fitness methods. the ministry of health, the ministry of education and the general administration of sports of china have vigorously promoted it as one of the contents of health and physical education classes, and promoted it as a health qigong method throughout mainland china. it can be seen that baduanjin's gentle and non-aggressive movements are suitable for physical training for people of all ages.


Eligibility criteria:
inclusion criteria: * (1) old person able to communicate and follow instructions, (2) stable and with sufficient physical strength: able to maintain at least one sitting position in a wheelchair or on the edge of a bed. exclusion criteria: * (1) difficulty standing or walking and obvious musculoskeletal disease, (2) diagnosed and recommended by a physician those who are not suitable for sports activities, (3) serious diseases/unstable conditions, such as severe cardiopulmonary, liver and kidney diseases, severe malignant tumors, severe malnutrition, severe dementia, (4) more than 180 minutes of exercise per week in the past month time, (5) severe arrhythmia, (6) no intention to participate.
efficacy of bgg492 in individuals with refractory partial seizures undergoing inpatient evaluation for epilepsy surgery

Conditions: Seizures; Epilepsy

Summary: this study will asses the safety and efficacy of bgg492 in reducing the seizure rate in therapy-refractory partial seizures.


Eligibility criteria:
inclusion criteria: 1. a diagnosis of partial seizures (with or without secondary generalization) and undergoing an evaluation for epilepsy surgery, based on the classification of the international league against epilepsy (ilae), as modified in 1981. 2. absence of evolving space-occupying lesions or progressive neurological diseases. 3. have normal vital signs (systolic and diastolic blood pressure and pulse rate) 4. all female subjects must have negative pregnancy test results 5. subjects must weigh at least 50 kg to participate in this study and must have a body mass index (bmi) within the range of 18 to 35. exclusion criteria: 1. a history of frequent and/or severe status epilepticus (i.e. requiring intensive care unit treatment). 2. current treatment with phenobarbital, primidone or zonisamide (these drugs would have to be completely washed out before study start) 3. having discontinued chronic benzodiazepine and barbiturate therapy within 30 days prior to the study start 4. having electrodes implanted in the brain. 5. having evidence on physical examination, or a history of any medically significant thyroid, cardiac, respiratory, hepatic, gastrointestinal, renal, hematologic, oncologic, psychiatric or progressive neurological disorder, requiring current medical intervention/therapy likely to have a significant impact on the outcome of this study. 6. with any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs, e.g. gi surgery and/or pancreatic or liver disease 7. having a significant illness other than epilepsy within two (2) weeks prior to initial dosing. 8. having recent (within the last three (3) years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc). other protocol-defined inclusion/exclusion criteria may apply

Keywords: epilepsy seizure monotherapy trials partial seizure partial seizures and undergoing evaluation for epilepsy surgery